Understanding co-morbidities affecting children with epilepsy.
Co-morbid conditions frequently occur in childhood epilepsy and may significantly affect epilepsy and its treatment. Similarly, epilepsy and antiepileptic drugs (AEDs) may affect these associated conditions. Co-morbidities that have a significant association with childhood epilepsy include attention-deficit/hyperactivity disorder, autism, developmental disabilities, accidental injury, migraine, and depression/anxiety. Understanding the interrelationships among co-morbidities, epilepsy, and their treatments is essential to optimal management of pediatric patients. Treatment should be individualized with consideration for specific co-morbidities and concomitant medications. Key treatment goals are to achieve seizure control and optimal physical and cognitive function using the simplest possible AED regimen. The clinician should consider whether an antiepileptic treatment can be chosen that also ameliorates the co-morbid condition. Newer AEDs, such as lamotrigine, topiramate, gabapentin, oxcarbazepine, and tiagabine, may benefit children with epilepsy and some co-morbid disorders.
Pellock
John M
JM
Virginia Commonwealth University/Medical College of Virginia, Richmond, VA 23298-0565, USA.
D000927:Anticonvulsants / Q000627:therapeutic use; D001289:Attention Deficit Disorder with Hyperactivity / Q000453:epidemiology; D001321:Autistic Disorder / Q000453:epidemiology; D002648:Child; D015897:Comorbidity; D003863:Depression / Q000453:epidemiology; D002658:Developmental Disabilities / Q000453:epidemiology; D004305:Dose-Response Relationship, Drug; D004827:Epilepsy / Q000188:drug therapy* / Q000453:epidemiology; D006801:Humans; D015994:Incidence; D008881:Migraine Disorders / Q000453:epidemiology; D015995:Prevalence; D012307:Risk Factors
D000927:Anticonvulsants